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Objective
• To evaluate the feasibility of using computer-assisted,
deformable image registration software to enable
three-dimensional (3D), multi-parametric (mp) magnetic
resonance imaging (MRI)-derived information on
tumour location and extent, to inform the planning and
conduct of focal high-intensity focused ultrasound
(HIFU) therapy.
Patients and Methods
• A nested pilot study of 26 consecutive men with a visible
discrete focus on mpMRI, correlating with positive
histology on transperineal template mapping biopsy, who
underwent focal HIFU (Sonablate 500®) within a
prospective, Ethics Committee-approved multicentre trial
(‘INDEX’).
• Non-rigid image registration software developed in our
institution was used to transfer data on the location and
limits of the index lesion as deﬁned by mpMRI.
• Manual contouring of the prostate capsule and
histologically conﬁrmed MR-visible lesion was
performed preoperatively by a urologist and
uro-radiologist.
• A deformable patient-speciﬁc computer model, which
captures the location of the target lesion, was
automatically generated for each patient and registered to
a 3D transrectal ultrasonography (US) volume using a
small number (10–20) of manually deﬁned capsule
points.
• During the focal HIFU, the urologist could add
additional sonications after image-registration if it was
felt that the original treatment plan did not cover the
lesion suﬃciently with a margin.
Results
• Prostate capsule and lesion contouring was achieved in
<5 min preoperatively. The mean (range) time taken to
register images was 6 (3–16) min.
• Additional treatment sonications were added in 13 of 26
cases leading to a mean (range) additional treatment time
of 45 (9–90) s.
Conclusion
• Non-rigid MR-US registration is feasible, eﬃcient and
can locate lesions on US.
• The process has potential for improved accuracy of focal
treatments, and improved diagnostic sampling strategies
for prostate cancer.
• Further work on whether deformable MR-US registration
impacts on eﬃcacy is required.
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Introduction
Tissue preserving, focal treatments for early prostate
cancer are currently under early phase evaluation within
prospective development studies with encouraging
early risk/beneﬁt ratio outcomes [1–3]. The early
proof-of-concept studies used treatment regions based on
anatomical boundaries rather than the tumour, e.g.
‘hemi-ablation’ [1,3]. More contemporary reports have
moved towards deﬁning targets and planned treatment
volumes by cancer foci, including a treatment margin [2].
This is established practice in radiation therapy, where the
process of treatment planning is heavily dependent on
imaging to deﬁne the gross tumour volume, clinical target
volume and planning target volume [4,5].
The key challenge in tissue-preserving focal ablative
methods is to enable the operator to target the tumour
volume during the ultrasound (US)-based procedure
(detected and deﬁned before treatment) with an
appropriate cancer margin, in a similar manner to the
treatment planning procedures used in radiotherapy. The
technical obstacles to this are signiﬁcant in that they must
account for diﬀerences between diagnostic images (often
multi-parametric (mp) MRI) and those images taken on the
treatment platform (often US), arising through position,
rotation, compression and swelling deformation. Further,
although novel MR-targeted ablative techniques are now
being described within small case series [6], these are
performed ‘in-bore’, which is costly, resource intensive, and
requires MR-compatible equipment. Image registration
aims to overcome these problems. The ability to
electronically translate and transfer information on cancer
burden, multiplicity and location to inform and direct
therapy is currently not a standard feature of most existing
ablative therapy platforms accessible to urologists.
Image-fusion technologies have now been developed for
aiding MRI-targeted biopsies to suspicious areas [7–10],
including several commercially available systems. However,
these systems have not yet been used for targeted,
tissue-preserving, therapies. Furthermore, many of these
systems do not account for the deformity issues described
above.
We have developed advanced, deformable, semi-automatic
image registration software at our institution to achieve
this. In the present study, we report on our early clinical
experience, which is the ﬁrst of this kind to our knowledge,
in the feasibility of using image-registration to guide and
deliver tissue preserving focal therapy by incorporating
three-dimensional (3D) MR-visible lesion information
(veriﬁed by transperineal template mapping biopsies) for
decisions on ablation margins.We nested a pilot study
within the ‘INDEX’ trial, a multi-centre, investigator-led,
UK National Cancer Research Network study evaluating
3-year outcomes after focal high-intensity focused
ultrasound (HIFU).Within the pilot study, we sought to
ﬁrstly assess the eﬃciency of work-ﬂows in clinically
integrating image-registration into the trial pathway, and
secondly, to ensure that the registered information could be
visualised and resembled the information obtained on
preoperative mpMRI. Thirdly, we aimed to obtain pilot
data on whether MR-US registration resulted in a change in
the treatment plan. As a pilot study, veriﬁcation that the
registration technique had any clinical utility within this
trial cohort was outside of the scope of this report.
Patients and Methods
A proof-of-concept feasibility study of image-registration
was nested within an existing registered, prospective, ethics
committee approved multicentre trial (‘INDEX’) of focal
therapy using HIFU (Sonablate 500®) (clinicaltrials.gov
NCT01194648); ‘INDEX’ meets the deﬁnition of a
Prospective Exploration study for surgical research [11]
and will eventually recruit 140 men with localised prostate
cancer (PSA level of 15 ng/mL, radiological T3aN0M0,
Gleason  4 + 3) who will be treated based on histological
ﬁndings from a 5-mm transperineal template-guided
mapping biopsy. Before treatment, all patients undergo
pre-biopsy mpMRI, including T2-weighting,
diﬀusion-weighting, and dynamic contrast-enhancement.
Our nested study involved integrating computer-assisted
MR-TRUS image registration software within the planning
and conduct of the ﬁrst 26 men treated with focal HIFU
who had an MR-lesion at one participating trial centre.
The objectives were to evaluate workﬂows, user interaction
and software to hardware integration and stability.We also
aimed to obtain pilot data on the extent to which the image
registration software aided our treatment planning when
deﬁning the margin around areas of MR-lesions.
Workflow for MR-directed therapy
Manual contouring of the prostate capsule and the
MR-visible lesion on transverse (axial) slices of the
T2-weighted MR volume was performed preoperatively by
a urologist (L.D.) and/or uro-radiologist (A.K., C.A.)
(Fig. 1). A 3D, deformable, patient-speciﬁc computer model
of the prostate and target lesion, which captures its
location, shape, and size was then generated automatically
for each patient using custom-written software developed
by our research group [12].
An important property of these computer models is that
they deform in a physically realistic way to compensate for
TRUS-probe induced shape changes that occur. This is
achieved by using computer simulations to predict the
plausible deformation of the prostate gland during the
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insertion of the TRUS probe.We have previously described
the full technical details [11,13].
Therapy Planning
The focal HIFU treatment protocol for ‘INDEX’was to treat
the prostate side that had the dominant or index lesion using
quadrant ablation, hemi-ablation, or hemi-ablation with
contralateral extension where disease crossed the mid-line
(maximum 60% gland ablation). The initial planning was
based on operator judgements, primarily based on position of
disease on template prostate-mapping biopsy and visual
inspection of the mpMR-images on a separate workstation.
This was carried out before the registration process.
Intraoperative Image Registration
After the initial cognitive based treatment plan,
intraoperative MR-TRUS registration was performed on a
separate computer workstation. The following steps were
required: ﬁrst, acquisition of a 3D TRUS volume using the
HIFU probe’s imaging facility; second, a number of points
were deﬁned on both sagittal and transverse images (10–30
points) to deﬁne the prostate contour on the US 3D
volume; and third, the MR-derived, patient-speciﬁc model
was then registered automatically to these points and
displayed as a graphical overlay on the TRUS image views,
as shown in Fig. 2 [11].
Therapy Planning Adjustment after Target Lesion
Registration
The target lesion volume was then displayed as a coloured
overlay on TRUS images as shown in Fig. 3 and Fig. 4. As
the objective was to evaluate the feasibility of using our
image-registration software in the clinical setting, best
ethical practice dictated that treatment volume could be
Fig. 1 Manual contouring of the MR-visible lesion on axial T2-weighted images from a preoperative mpMRI. Dynamic contrast-enhanced and
diffusion-weighted images are also displayed on the same screen.The prostatic capsule (contour 1) (apex to base) and the MR-visible lesion
(contour 2) were contoured separately.
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added but not subtracted after image-registration. This
ensured that cancer ablation was not compromised, and
only (possibly) enhanced.
Results
The clinical and tumour characteristics of the men treated
are detailed in Table 1. T-stage was based on radiological
stage from mpMRI as is standard practice in our cancer
network. In the ﬁrst 26 cases reported here, the intention
was to verify that use of the image-registration process in
the clinical setting would not interfere adversely with the
intraoperative workﬂow. Information on location of the
index lesion was concordant between mpMRI and template
biopsy in all cases. There were no adverse events reported
as a result of using the image-registration software. The
HIFU device did not report any technical issues or
problems when linked to the external computer
workstation housing the image-registration software. The
registered lesion appeared appropriately depicted on the
HIFU device, correlating with expected position and
volume (for the pixel size used). Prostate capsule and lesion
contouring could be achieved in <5 min preoperatively.
The mean (range) time taken to register images was
6 (3–16) min. This was measured from the time that the
TRUS volume was transferred onto the separate
workstation running the registration software to the time of
visualising the MR-registered lesion on the HIFU device.
The initial ablation plan was modiﬁed to treat additional
tissue in 13 of 26 cases leading to a mean (range) additional
treatment time of 45 (9–90) s, equating to between one and
10 additional treatment sonications, within a mean (range)
overall theatre time of 141 (95–200) min. Postoperative
biochemical and histological outcomes are subject to a
pre-deﬁned protocol, with reporting time-points governed
by a Trial Steering Committee.
Discussion
We have shown that deformable image registration is
feasible and safe when introduced into an ablative therapy
setting. Moreover, most of the additional workﬂow and
time can be carried out elsewhere with minimal time
required in the operating room. Further, there is the
potential for improving the accuracy of incorporating a
therapeutic margin and targeting lesions within a
tissue-preserving focal therapy approach.
Indeed, if on-going clinical trials show clinical utility for
focal therapy within standard care, it is possible that
image-registration software may be essential for the
eﬃcient implementation of truly focal therapy techniques
in which individual tumours are treated within an
appropriate and safe surgical margin. As shown in the
present series, even when quadrant or lobe ablations are
used, automated registration resulted in additional
treatment volume in half of the cases. The volume added
equated to up to approximately 1 mL of tissue and may
have an impact on disease-free status.Within the conﬁnes
of a nested pilot study, we will not be able to truly verify
any disease-control advantage. There appeared to be no
correlation between tumour position and the addition of
treatment sonications, albeit that most patients had
peripheral zone lesions. In particular, two patients had
radiological T3a disease, but treatment was added in only
one of these cases.
There are several commercially available software-driven
devices that aim to register MRI data with US images for
the purposes of prostate biopsy and therapy guidance.
However, a signiﬁcant limitation of many of these
Fig. 2 A and B. An automatically generated 3D, deformable,
patient-specific computer model of the prostate and target lesion
(shown in orange) using the custom-written software developed by
our research group [11].
A
B
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techniques is that, unlike the software used in the present
series, changes in the size and shape of the prostate that
result from diﬀerences in patient position and the insertion
of a TRUS probe (and/or an endorectal MR coil) are not
compensated for. More sophisticated deformable, or
‘non-rigid’, registration methods, include those that have
only been validated using a phantom, and require full
contouring of the prostate in TRUS images [14,15]. This is
time-consuming and undesirable in the intraoperative
setting. Some recent series have reported good accuracy of
their deformable method on phantom and clinical images,
but without therapeutic application of their results [16,17].
Our group has recently described a deformable
image-registration method that automatically aligns an MR
image to a 3D TRUS image [4], with a registration accuracy
of 2.40 mm. In the present study, we used an adapted,
semi-automatic version of the algorithm described in our
earlier work for which a number of user-deﬁned prostate
capsule points were identiﬁed in 3–5 TRUS image slices
without the need to contour the entire gland. This resulted
in a system that was robust to the variable quality of
diﬀerent TRUS imaging systems.
There are several limitations to the present study. First,
although our image-registration process takes an average
time of <10 min, additional time was required to manually
contour the lesion and prostatic capsule on MR-images,
and to pre-process the MRI data before therapy. This
timescale was not incorporated into the present results.
Second, although prostate tumours are not always most
clearly visualised on the T2-weighted sequence, contouring
could only be performed using this sequence on the
current software. However, diﬀusion-weighted and dynamic
contrast-enhanced sequences could also be visualised
within the same screen at the time of contouring for
reference. Third, for these ﬁrst few cases, expert knowledge
from members of the radiology, urology and computing
departments was required. This was anticipated and with
increased use and experience, and reﬁnement of the
software interface, it is likely that the time and person
burden will diminish. The learning curve is likely to mirror
that of most image-based procedures. Finally, whilst we did
add sonications to our original operator-deﬁned treatment
plans as a result of image-registration, within this feasibility
study it was not our intention to evaluate the impact on
cancer control. This will ideally require a randomised
comparative approach of cognitive based treatment
planning vs an automated computer based
image-registration driven plan.We plan to do this once the
pre-deﬁned protocol for the ﬁrst 140 men treated in the
‘INDEX’ trial is complete.
Although the clinical adoption of an MR-directed therapy
is likely to add cost to existing workﬂows and pathways, it
may provide potential for overall health economic saving in
the future through improved cancer diagnosis (through
image-targeted biopsy) and improved therapeutic cancer
control. The use of MR-US registration potentially provides
Fig. 3 A screenshot of the image registration software: The patient-specific deformable model (green and blue) is displayed as a graphical
overlay on the real-time TRUS images (taken from the HIFU device) after registration. This was preceded by manual definition of the limits of
prostatic capsule in the TRUS image and the definition of 10–20 user-defined points on at least one transverse and sagittal slices.
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a highly cost-eﬀective solution that, as shown in the present
study, can be easily integrated within existing workﬂows
and interfaces, with standard surgical equipment. However,
we accept that formal cost analyses will be required, to
further quantify this.
To the best of our knowledge, this is the ﬁrst report of
integrating a deformable, non-rigid, image-registration
system for MR-directed HIFU therapy planning. If further
evaluation shows a high level of accuracy, ease-of-use, and
inter-observer reproducibility, integration of this software
may allow improved accuracy of targeting and delivery of
highly selective tissue treatment, with minimal burden to
resources, and easy adoption by clinicians if focal therapy is
shown to have a role in standard clinical practice.
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